Development of a sandwich ELISA for evaluating soluble OX40L (CD252) in human sera of different ages or with Graves' disease

Cytokine

Volumn 36, Issue 1-2, 2006, Pages 23-28

  Wang, Qin ^a   Chen, Yongjing ^a,b   Xie, Fang ^a,b   Ge, Yan ^a,b   Chen, Lei ^c   Wu, Hongya ^a   Qu, Qiuxia ^a,b   Wang, Xuefeng ^a   Zhang, Xueguang ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b Clinical Immunology Research Laboratory of Jiangsu Province   (China)

^c No 2 Hospital of Suzhou   (China)

Author keywords

Age; ELISA; Graves' disease; OX40L; Soluble

Indexed keywords

CD134 ANTIGEN; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1G1; MONOCLONAL ANTIBODY 4C12; OX40 LIGAND; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; CELL LINE; CHINA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAVES DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; SERUM;

AGED; AGED, 80 AND OVER; AGING; ANIMALS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAVES DISEASE; HUMANS; MICE; MIDDLE AGED; OX40 LIGAND; SOLUBILITY;

EID: 33846005516     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.10.006     Document Type: Article

References (20)

1. Kohno T., Brewer M.T., Baker S.L., Schwartz P.E., King M.W., Hale K.K., et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87 (1990) 8331-8335
2. Pizzolo G., Vinante F., Chilosi M., Dallenbach F., Josimovic-Alasevic O., Diamantstein T., et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 75 (1990) 282-284
3. Viallard J.F., Solanilla A., Gauthier B., Contin C., Déchanet J., Grosset C., et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 99 (2002) 2612-2614
4. Henn V., Steinbach S., Büchner K., Presek P., and Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98 (2001) 1047-1054
5. Jung H.W., Choi S.W., Choi J.I., and Kwon B.S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 36 (2003) 13-22
6. Vakkalanka R.K., Woo C., Kirou K.A., Koshy M., Berger D., and Crow M.K. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42 (1999) 871-881
7. Salih H.R., Nuessler V., Denzlinger C., Starling G.C., Kiener P.A., and Schmetzer H.M. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. Leuk Lymphoma 45 (2004) 301-308
8. Tortorella C., Sacco R., Orlando P., Salerno M.T., Schiraldi O., and Antonaci S. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology. Immunopharmacol Immunotoxicol 22 (2000) 19-33
9. Miura S., Ohtani K., Numata N., Niki M., Ohbo K., Ina Y., et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specificallt induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 11 (1994) 1313-1325
10. Stuber E., Neurath M., Calderhead D., Fell H.P., and Strober W. Crosslinking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2 (1995) 507-521
11. Stuber E., and Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T-cell dependent humoral immune response. J Exp Med 183 (1996) 979-989
12. Ohshima Y., Tanaka Y., Tozawa H., Takahashi Y., Maliszewski C., and Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 159 (1997) 3838-3848
13. Imura A., Hori T., Imada K., Ishikawa T., Tanaka Y., Maeda M., et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 183 (1996) 2185-2195
14. Pipping S.D., Pena-Rossi C., Long J., Godfrey W.R., Fowell D.J., Reiner S.L., et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 163 (1999) 6520-6529
15. Gramaglia I., Andrew D.W., Michael L., and Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell response. J Immunol 161 (1998) 6510-6517
16. Rogers P.R., Song J., Gramaglia I., Killeen N., and Croft M. OX40 promotes Bcl-xl and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15 (2001) 445-455
17. Wang Q., Cheng Y.J., Ge Y., Sun J.J., Shi Q., Ju S.W., et al. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signaling: enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens 64 (2004) 566-574
18. Chiyoko N., Hisaya A., and Atsuo N. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 166 (2001) 2108-2115
19. Taro Y., Atsuo N., and Hisaya A. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 30 (2000) 2815-2823
20. Wang X., Ria M., Kelmenson P.M., Eriksson P., Higgins D.C., Samnegard A., et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 37 (2005) 365-372